Literature DB >> 18315691

Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy.

Christine Tunon-de-Lara1, Sylvia Giard, Max Buttarelli, Jérome Blanchot, Jean-Marc Classe, Marc Baron, Brice Monnier, Gilles Houvenaeghel.   

Abstract

Axillary lymph node dissection in patients with ductal carcinoma in situ (DCIS) of the breast is not warranted because DCIS has no metastatic potential. However, the risk of microinvasive carcinoma (MIC) exists in large DCIS treated by mastectomy. The aim of this series is to evaluate the incidence of lymph node metastases in DCIS and DCIS-MIC. We analyzed retrospectively patients treated in six French cancer centers for pure DCIS or DCIS-MIC. Surgical procedures were lumpectomy or mastectomy associated with an axillary sentinel node (SN) procedure. We included 161 patients suffering from pure DCIS (116/161, 72%) or DCIS-MIC (45/161, 28%). Mean age was 56 years (32-78). We observed underestimation between core biopsy and histological result in 43/142 cases (30%). These data show an association between lesion size, solid subtype, high-grade DCIS, and underestimation. Forty-eight breast conservative procedures were performed and 113 mastectomies (70%). SN procedure was performed using blue dye, technetium, or both. In our series, we selected patients with a high risk of occult invasive carcinoma: high grade (55%), mean size (27 mm), and mastectomy (112). Six SN were found positive (3.7%). In the five patients treated with complete axillary dissection, the SN was the only positive node. SN in DCIS is an interesting procedure but not necessary for all patients. We need to focus on the subgroup with or a high risk of occult MIC: extensive calcifications or palpable mass, DCIS diagnosed by core biopsy and underestimation, multifocality, high grade, large tumor size, MIC, and mastectomy.

Entities:  

Mesh:

Year:  2008        PMID: 18315691     DOI: 10.1111/j.1524-4741.2007.00543.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  9 in total

1.  Sentinel lymph node biopsy in clinically detected ductal carcinoma in situ.

Authors:  Ahmed Yahia Al-Ameer; Sahar Al Nefaie; Badria Al Johani; Ihab Anwar; Taher Al Tweigeri; Asma Tulbah; Mohmmed Alshabanah; Osama Al Malik
Journal:  World J Clin Oncol       Date:  2016-04-10

2.  Sentinel lymph node biopsy in selected cases of ductal carcinoma in situ.

Authors:  María Vicenta Collado; Jaime Ruiz-Tovar; Augusto García-Villanueva; Roberto Rojo; Lucía Latorre; María Eugenia Rioja; Fernando González-Palacios
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

Review 3.  The impact of sentinel lymph node biopsy and magnetic resonance imaging on important outcomes among patients with ductal carcinoma in situ.

Authors:  Todd M Tuttle; Tatyana Shamliyan; Beth A Virnig; Robert L Kane
Journal:  J Natl Cancer Inst Monogr       Date:  2010

4.  The Role of Sentinel Lymph Node Biopsy and Factors Associated with Invasion in Extensive DCIS of the Breast Treated by Mastectomy: The Cinnamome Prospective Multicenter Study.

Authors:  Christine Tunon-de-Lara; Marie Pierre Chauvet; Marie Christine Baranzelli; Marc Baron; Jean Piquenot; Guillaume Le-Bouédec; Fréderique Penault-Llorca; Jean-Rémi Garbay; Jérôme Blanchot; Joëlle Mollard; Véronique Maisongrosse; Simone Mathoulin-Pélissier; Gaëtan MacGrogan
Journal:  Ann Surg Oncol       Date:  2015-03-17       Impact factor: 5.344

5.  The Demographic Features, Clinicopathological Characteristics and Cancer-specific Outcomes for Patients with Microinvasive Breast Cancer: A SEER Database Analysis.

Authors:  Wenna Wang; Wenjie Zhu; Feng Du; Yang Luo; Binghe Xu
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

6.  Risk factors for lymph node metastasis and the impact of adjuvant chemotherapy on ductal carcinoma in situ with microinvasion: a population-based study.

Authors:  Cong Chen; Shumin Huang; Aihua Huang; Yunlu Jia; Ji Wang; Zeqin Zhang; Misha Mao; Linbo Wang; Jichun Zhou
Journal:  Onco Targets Ther       Date:  2018-12-13       Impact factor: 4.147

7.  High and intermediate grade ductal carcinoma in-situ of the breast: a comparison of pathologic features in core biopsies and excisions and an evaluation of core biopsy features that may predict a close or positive margin in the excision.

Authors:  Oluwole Fadare; Nathan F Clement; Mohiedean Ghofrani
Journal:  Diagn Pathol       Date:  2009-08-19       Impact factor: 2.644

8.  Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ: French Survey experience.

Authors:  B Cutuli; C Lemanski; A Fourquet; B de Lafontan; S Giard; A Meunier; R Pioud-Martigny; F Campana; H Marsiglia; S Lancrenon; E Mery; F Penault-Llorca; E Fondrinier; C Tunon de Lara
Journal:  Br J Cancer       Date:  2009-03-10       Impact factor: 7.640

9.  Educational Case: Ductal Carcinoma In Situ (DCIS).

Authors:  Miglena K Komforti; Bryan E Harmon
Journal:  Acad Pathol       Date:  2019-11-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.